Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Appendix B: Panel Roster and Financial Disclosures

Hepatitis C Virus

Last Updated: January 1, 2020; Last Reviewed: August 1, 2019

Hepatitis C Virus 
Member Financial Disclosure
Company Relationship
Bansal, Meena Mount Sinai Hospital None N/A
Kim, Arthur
Harvard Medical School BioMarin, Inc. Advisory Board
UpToDate Royalties
Kim, Nina University of Washington None N/A
Naggie, Susanna Duke University Abbvie Research Support
BioMarin, Inc Advisory Board
FHI 360 Event Adjudication Committee
Gilead Sciences Research Support
PRA Health Sciences/Bristol-Myers Squibb Event Adjudication Committee
Vir Biotechnology Scientific Advisor (stock option)
Sulkowski, Mark* Johns Hopkins University AbbVie Advisory Board, Research Support
Gilead Sciences Advisory Board, Data Safety Monitoring Board, Research Support
Villanueva, Merceditas Yale University School of Medicine None N/A
Wyles, David Denver Health Medical Center and University of Colorado School of Medicine Gilead Sciences Research Support
* Group lead

Note: Members were asked to disclose all relationships from 12 months prior to the reviewed date. The period of reporting was from August 1, 2018, through August 1, 2019

Download Guidelines